Envestnet Asset Management’s AllianzIM U.S. Equity Buffer20 Mar ETF MARW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$918K Buy
26,923
+6,065
+29% +$209K ﹤0.01% 3519
2025
Q4
$716K Sell
20,858
-2,167
-9% -$73.4K ﹤0.01% 3460
2025
Q3
$774K Sell
23,025
-493
-2% -$16.3K ﹤0.01% 3475
2025
Q2
$765K Sell
23,518
-3,152
-12% -$98.7K ﹤0.01% 3425
2025
Q1
$826K Buy
26,670
+10,651
+66% +$334K ﹤0.01% 3317
2024
Q4
$497K Sell
16,019
-182,862
-92% -$5.64M ﹤0.01% 3586
2024
Q3
$6.05M Buy
198,881
+5,294
+3% +$158K ﹤0.01% 1978
2024
Q2
$5.71M Buy
193,587
+10,722
+6% +$309K ﹤0.01% 1932
2024
Q1
$5.25M Buy
+182,865
New +$5.17M ﹤0.01% 1942

Other funds holding MARW

Envestnet Asset Management's MARW Position: Q1 2026 in Review

Envestnet Asset Management increased its AllianzIM U.S. Equity Buffer20 Mar ETF (MARW) stake by 29% in Q1 2026, buying an estimated $209K and bringing the position to 26,923 shares worth $918K. The position accounts for ﹤0.01% of the portfolio, ranked #3519.

Envestnet Asset Management first reported a position in MARW in Q1 2024 and has held it in 9 quarters since. The position peaked at $6.05M in Q3 2024. 40 funds tracked by Wall St. Rank hold MARW as of Q1 2026.

  • Envestnet Asset Management held 26,923 shares of AllianzIM U.S. Equity Buffer20 Mar ETF worth $918K as of Q1 2026.
  • Envestnet Asset Management bought 6,065 AllianzIM U.S. Equity Buffer20 Mar ETF shares in Q1 2026, an estimated $209K.
  • AllianzIM U.S. Equity Buffer20 Mar ETF made up ﹤0.01% of Envestnet Asset Management's portfolio in Q1 2026, its #3519 holding.
  • Envestnet Asset Management first reported a position in AllianzIM U.S. Equity Buffer20 Mar ETF in Q1 2024 and has held it in 9 quarters since.
  • Envestnet Asset Management's AllianzIM U.S. Equity Buffer20 Mar ETF position peaked at $6.05M in Q3 2024.
  • 40 funds tracked by Wall St. Rank held AllianzIM U.S. Equity Buffer20 Mar ETF as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.